Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Wades Into ‘Rebate Walls’ And Biosimilar Access With Remicade Investigation

Executive Summary

Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.

You may also be interested in...



Anticompetitive Drug Rebates May Need FTC Rulemaking For Timely Reform, Commissioners Say

‘Rebate walls’ report heads to US Congress, but Democratic commissioners suggest FTC’s typical approach to curtailing such practices is too time consuming.

Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy

Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.

Point-Of-Sale Rebates May Be Added To US Senate Finance Drug Pricing Bill

Legislation clears committee with no major changes. However, the number of Republicans opposing the bill due to concerns over price inflation rebates portend difficulties ahead for a floor vote.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel